Connective tissue diseases: Belimumab for systemic lupus erythematosus: Breaking through?

Nature Reviews Rheumatology

Volumn 6, Issue 3, 2010, Pages 124-125

  Dall'Era, Maria ^a   Wofsy, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB;

B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; RATING SCALE; SHORT SURVEY; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 77749270418     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.20     Document Type: Short Survey

References (7)

1. Wallace, D. J. et al. A phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumab of patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
2. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103-1112 (2009).
3. Merrill, J. T. et al. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. Presented at the American College of Rheumatology 2008 Annual scientific Meeting.
4. Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study (EXPLORER). Presented at the American College of Rheumatology 2008 Annual Scientific Meeting.
5. Furie, R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 60 (suppl.), S429 (2009).
6. Navarra, S. et al. Belimumab, a BLys-Specific inhibitor, reduced disease activity, flares, and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Presented at the American College of Rheumatology 2009 Annual Scientific Meeting.
7. Glaxosmith Kline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus. GlaxosmithKline [online] http://www.gsk.com/media/pressreleases/2009/2009- pressrelease-10121.htm (2009).